Patents by Inventor Supriya PATEL
Supriya PATEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965020Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: GrantFiled: May 17, 2023Date of Patent: April 23, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
-
Publication number: 20230391844Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2R? moiety and a protease-cleavable linker, configured such that the IL2R? moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.Type: ApplicationFiled: June 2, 2023Publication date: December 7, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Jiaxi WU, Supriya PATEL, Tong ZHANG, Nicolin BLOCH, Eric SMITH, Chia-Yang LIN, Vidur GARG, Erica ULLMAN
-
Publication number: 20230382969Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2R? moiety and a protease-cleavable linker, configured such that the IL2R? moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.Type: ApplicationFiled: May 26, 2023Publication date: November 30, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Supriya PATEL, Tong ZHANG, Jiaxi WU, Aaron CHANG, Eric SMITH, Chia-Yang LIN, Samuel DAVIS
-
Publication number: 20230340105Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: ApplicationFiled: May 17, 2023Publication date: October 26, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
-
Publication number: 20230287117Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcy receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcy receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.Type: ApplicationFiled: October 6, 2022Publication date: September 14, 2023Inventors: Samuel Davis, Eric Smith, Tong Zhang, Supriya Patel
-
Patent number: 11708407Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: GrantFiled: February 7, 2022Date of Patent: July 25, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
-
Patent number: 11518807Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc? receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc? receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.Type: GrantFiled: December 19, 2019Date of Patent: December 6, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Eric Smith, Tong Zhang, Supriya Patel
-
Publication number: 20220235126Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: ApplicationFiled: February 7, 2022Publication date: July 28, 2022Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chiayang Lin, Samuel Davis
-
Publication number: 20220195030Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: ApplicationFiled: February 7, 2022Publication date: June 23, 2022Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chiayang Lin, Samuel Davis
-
Publication number: 20210246207Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.Type: ApplicationFiled: March 30, 2021Publication date: August 12, 2021Inventors: Samuel Davis, Eric Smith, Supriya Patel
-
Patent number: 10988537Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.Type: GrantFiled: September 12, 2018Date of Patent: April 27, 2021Assignee: Regeneren Pharmaceuticals, Inc.Inventors: Samuel Davis, Eric Smith, Supriya Patel
-
Publication number: 20210040197Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: ApplicationFiled: August 7, 2020Publication date: February 11, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chiayang Lin, Samuel Davis
-
Publication number: 20200109203Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc? receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc? receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.Type: ApplicationFiled: December 19, 2019Publication date: April 9, 2020Inventors: Samuel Davis, Eric Smith, Tong Zhang, Supriya Patel
-
Patent number: 10556952Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc? receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc? receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.Type: GrantFiled: March 30, 2016Date of Patent: February 11, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Eric Smith, Tong Zhang, Supriya Patel
-
Publication number: 20180371090Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.Type: ApplicationFiled: September 12, 2018Publication date: December 27, 2018Inventors: Samuel Davis, Eric Smith, Supriya Patel
-
Patent number: 10106610Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.Type: GrantFiled: May 5, 2016Date of Patent: October 23, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Eric Smith, Supriya Patel
-
Publication number: 20180282411Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc? receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc? receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.Type: ApplicationFiled: March 30, 2016Publication date: October 4, 2018Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Eric Smith, Tong Zhang, Supriya Patel
-
Publication number: 20160347839Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.Type: ApplicationFiled: May 5, 2016Publication date: December 1, 2016Inventors: Samuel Davis, Eric Smith, Supriya Patel
-
Patent number: 9359437Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.Type: GrantFiled: January 31, 2014Date of Patent: June 7, 2016Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Eric Smith, Supriya Patel
-
Publication number: 20140243504Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.Type: ApplicationFiled: January 31, 2014Publication date: August 28, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Samuel DAVIS, Eric SMITH, Supriya PATEL